Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis

BACKGROUND: Sugemalimab is a newly developed inhibitor of programmed death ligand 1 (PD-L1). As a first-line treatment for metastatic non-small-cell lung cancer (NSCLC), sugemalimab plus chemotherapy (Sugema-Chemo) has been proven effective. Still, its cost-effectiveness has not yet been determined....

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xueyan, Chen, Xiaoyu, Li, Huijuan, Liu, Xiaoxia, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008846/
https://www.ncbi.nlm.nih.gov/pubmed/36923040
http://dx.doi.org/10.3389/fpubh.2023.1054405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008846/
https://www.ncbi.nlm.nih.gov/pubmed/36923040
http://dx.doi.org/10.3389/fpubh.2023.1054405

Ejemplares similares